Join        Login             Stock Quote

ProMetic Reports Its Third Quarter 2012 Highlights and Financial Results

Tuesday, November 13, 2012 10:05 AM


LAVAL, QUEBEC, CANADA -- (Marketwire) -- 11/13/12 -- ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic" or the "Corporation") today reported revenues of $7.7 million, net profit of $2.5 million and earnings per share of $0.01 for the third quarter ended September 30, 2012 driven by strengthening product sales as well as increased services and licensing revenues from ProMetic's protein technologies business.

"Following a profitable Q2, our third quarter results continue to demonstrate the recurring revenue generation from our secured contracts and further diversifying of multiple revenue streams. With one quarter left in 2012, we are well underway to surpass our previously disclosed 2012 corporate objectives", stated Mr. Pierre Laurin, ProMetic's President and Chief Executive Officer.

Third Quarter 2012 Highlights

Business Highlights

The Corporation continued to deliver on the previously secured orders included in its original 2012 projected $21 million base case business. The Corporation also added to its pipeline of business for the remainder of 2012 and 2013 providing significant revenue upside and a continued reduction in the requirement for future cash injection.

ProMetic secured:

--  An $11 million agreement, for its Protein Technologies division,
    relating to research, development and commercial activities with
    Shenzhen Hepalink Co., Ltd project based on its proprietary protein
    technologies: The agreement includes $11 million in licensing fees and
    milestone payments to ProMetic, of which $2 million was paid up front.
    In addition, ProMetic will also receive further fees for product
    development activities to be performed on behalf of Hepalink. Work is
    expected to commence in the fourth quarter of 2012. 
--  ProMetic also entered into a strategic investment agreement with
    Shenzhen Hepalink Co.,Ltd consisting of a $10.0 million equity
    investment in ProMetic at $0.204 per share, representing a 63% premium
    to the stock market price of the day prior to the announcement. In
    exchange, ProMetic will issue 48,147,053 shares representing
    approximately 10.02% of the corporation's outstanding shares on a post-
    transaction basis. The issued shares will be subject to a three (3) year
    hold period. The investment is conditional to regulatory approval by the
    parties' respective regulatory authorities.  

Third Quarter Financial Results and Outlook

The financial information in regards to the three month period ended September 30, 2012 should be read in conjunction with the Corporation's financial statements as well as the Management's Discussion and Analysis dated November 13, 2012.

Total revenues for the third quarter of 2012, which were derived from product sales, development services and licensing revenues, were $7.7 million compared with $3.3 million for the same quarter of 2011. Total revenues for the first 9 months of 2012 were $15.1 million compared to $9.1 million for the first 9 months of 2011.

ProMetic generated a net profit of $2.5 million for the quarter ended September 30, 2012, as compared to a net loss of $2.1 million for the quarter ended September 30, 2011 and a net loss of $1.4 million after the first 9 months of 2012 compared to a net loss of $6.6 million for the first 9 months of 2011.

"The combination of our expanding commercial activities coupled with the execution of recent strategic agreements will provide significant upside to revenues. This consequently results in a reduction in expected financing requirements for the coming quarters. We have already made significant progress in improving most of our key financial metrics compared to the same period of last year and expect this trend to continue", said Mr. Bruce Pritchard, ProMetic's Chief Financial Officer.

ProMetic's management believes that despite the financial hurdles of 2011 and weaker results of the first quarter of 2012, the Company has made significant progress on securing a solid revenue stream for the last quarter of 2012 and beyond as evidenced by the second and now third quarter results.

Third Quarter 2012 Conference Call Information

ProMetic will host a conference call at 11:30am (EST) on Wednesday, November 14, 2012. The telephone numbers to access the conference call are (416) 981-9001 (International) and 1-800-891-6979 (Toll-free). A replay of the call will be available from November 14, 2012 1:30pm until November 21, 2012. The numbers to access the replay are 1-416-626-4100 (21611217) and 1-800-558-5253 (21611217). A live audio webcast of the conference call will be available through the following: http://www.gowebcasting.com/4006

Additional Information in Respect to the Three month Period ended September 30, 2012

ProMetic's MD&A and 2012 Third Quarter Financial Statements have been filed on Sedar (www.sedar.com) and are available on the Company's website at www.prometic.com.

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. ("ProMetic") (www.prometic.com) is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand(TM) technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Laval (Canada), ProMetic has R&D facilities in the U.K., the U.S. and Canada, manufacturing facilities in the U.K. and business development activities in the US, Europe, Asia and in the Middle-East.

Forward Looking Statements

This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward -looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 24 of ProMetic's Annual Information Form for the year ended December 31, 2011, under the heading "Risk and Uncertainties related to ProMetic's business". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.

Pierre Laurin
President and CEO
ProMetic Life Sciences Inc.

Frederic Dumais
Director, Communications & Investor Relations
ProMetic Life Sciences Inc.

(Source: Market Wire )
(Source: Quotemedia)


Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.